CJC 1295

Product Specifications

CAS: 863288-34-0

Also Known As: Modified GRF 1-29, CJC-1295 No DAC, Mod GRF(1-29)

Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂

Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂

Molecular Weight: 3367.9 Da

Purity: 99%+ (verified by HPLC)

Appearance: White to off-white lyophilized powder

Form: Lyophilized (freeze-dried)

Classification: GHRH Analogue (Growth Hormone Releasing Hormone Analogue)

CJC 1295 No DAC vs With DAC

CJC 1295 No DAC (Modified GRF 1-29) has an active half-life of approximately 30 minutes. Each administration produces a discrete GH pulse that closely mimics the body's natural pulsatile secretion rhythm. CJC 1295 with DAC includes a Drug Affinity Complex that binds the peptide to circulating albumin, extending its half-life to 6-8 days and producing a sustained GH elevation rather than a pulse. The No DAC form is preferred in research protocols that aim to replicate natural GH pulsatility.

Storage

CJC 1295 vials must be stored in a cool, dry place away from direct sunlight. Unreconstituted CJC 1295 peptide should be kept at -20°C for long-term storage or 2-8°C for short-term use. Once reconstituted with bacteriostatic water, CJC 1295 should be refrigerated at 2-8°C and used within 28-30 days. CJC-1295/ipamorelin storage temperature post-reconstitution follows the same standard for both peptides. Do not freeze reconstituted solutions.

Solubility

CJC 1295 is freely soluble in bacteriostatic water and sterile saline. Gently swirl the vial after adding solvent. Do not vortex or shake vigorously, as this may damage the peptide structure.

Intended Use

CJC 1295 is intended for research purposes only and is not approved for human use.

What Does CJC 1295 Do? GHRH Receptor Activation and GH Stimulation

• CJC 1295 is a 29-amino acid GHRH analogue incorporating four strategically placed amino acid substitutions that significantly increase its resistance to enzymatic degradation compared to native GHRH(1-29). It acts by selectively binding to and activating GHRH receptors in the anterior pituitary, triggering the synthesis and pulsatile release of growth hormone.
• Pharmacological research on CJC-1295 demonstrates dose-dependent increases in mean GH concentrations ranging from 2-10-fold above baseline, accompanied by IGF-1 elevations of 1.5-3-fold. These findings establish CJC 1295 peptide as a potent activator of the somatotropic axis.
• CJC-1295 side effects observed in research settings are consistent with GH pathway stimulation, including transient changes in glucose and insulin levels. The No DAC form's short active half-life naturally limits continuous GH exposure between administrations.
• Sermorelin vs CJC 1295: sermorelin is a 29-amino acid fragment matching the native GHRH sequence, while CJC 1295 includes four stabilizing amino acid substitutions that produce a more enzymatically resistant and longer-acting molecule. Research shows CJC-1295 generates a more robust and sustained GH pulse than sermorelin at equivalent doses.

CJC 1295 Ipamorelin: The Most Studied GH Combination Stack

• The CJC 1295 ipamorelin combination is the most studied dual-peptide GH stack in preclinical research. CJC-1295 activates GHRH receptors via the adenylyl cyclase/cAMP signaling pathway, while ipamorelin activates GHS-R (ghrelin receptors) via the phospholipase C/calcium pathway. Both pathways converge on GH secretion from pituitary somatotrophs, producing a synergistic release.
• Research on combined GHRH and GHRP administration consistently shows a GH pulse that substantially exceeds what either compound achieves independently. CJC 1295 ipamorelin benefits in preclinical models include amplified GH pulse amplitude, elevated IGF-1, and measurable effects on lean mass and body composition markers.
• CJC 1295 ipamorelin dosage in research protocols typically uses matched concentrations of both peptides administered together. Ipamorelin CJC 1295 dosage studies commonly target a fasted state for administration to maximize GH pulse amplitude and align with natural secretion rhythms.
• CJC 1295 ipamorelin shelf life after reconstitution follows standard peptide guidelines. Reconstituted solutions stored at 2-8°C should be used within 28-30 days. When preparing a CJC 1295 ipamorelin bacteriostatic water mix, introduce solvent gently and avoid shaking to maintain peptide integrity.

CJC 1295 Benefits for Muscle Growth and Body Composition

• CJC 1295 for muscle growth is one of the primary research applications of GHRH analogues. Elevated GH drives hepatic production of IGF-1, which activates the PI3K/Akt/mTOR signaling cascade in skeletal muscle, a well-characterized pathway responsible for muscle protein synthesis and lean mass development.
• Preclinical research demonstrates that sustained GHRH analogue administration produces measurable increases in lean body mass and circulating IGF-1 in animal models, supporting CJC 1295 benefits for body composition research across multiple model systems.
• CJC 1295 before and after comparisons in preclinical studies show statistically significant improvements in lean-to-fat mass ratios over research periods of 4-8 weeks, attributed to the combined effects of elevated GH pulsatility and elevated IGF-1 on anabolic and lipolytic signaling.
• CJC 1295 ipamorelin results in combination research show compound effects on body composition that exceed monotherapy findings, with CJC 1295 ipamorelin results timeline typically showing measurable IGF-1 and body composition changes within 4-6 weeks of consistent administration in animal models.

CJC 1295 Dosage for Research

CJC 1295 dosage used in preclinical and pharmacological research varies by study design and the form studied. CJC 1295 dosing protocols in published literature include:

• CJC-1295 No DAC (Modified GRF 1-29): 100-300 mcg per administration, once to twice daily in animal models, timed to replicate natural pulsatile GH release patterns.
• CJC-1295 with DAC: 30-60 mcg/kg in pharmacokinetic studies, administered once or twice weekly given the compound's 6-8-day active half-life.
• CJC 1295 ipamorelin dosage per day (combination): Matched concentrations of both peptides administered together, typically once or twice daily via subcutaneous injection. CJC-1295 ipamorelin dosage calculator tools can assist in converting body-weight-based study doses to injection volumes.

CJC 1295 dosage and timing in research protocols commonly targets administration in a fasted state or prior to rest cycles to maximize GH pulse amplitude, consistent with the natural suppression of GH secretion during fed states. CJC-1295 ipamorelin dosage per day and CJC-1295 dac dosage per day differ substantially due to the DAC form's extended half-life.

Research Protocol Notes

CJC 1295 is supplied as a lyophilized (freeze-dried) powder to ensure stability during storage and transport. For research use, the peptide must be reconstituted using bacteriostatic water or sterile saline. Introduce the solvent slowly down the inside wall of the vial and gently swirl to dissolve. Do not shake or vortex the solution. CJC-1295/ipamorelin storage temperature post-reconstitution should be maintained at 2-8°C and the solution used within 28-30 days. When preparing a CJC 1295 ipamorelin bacteriostatic water mix, maintain the same handling standards for both peptides. Unreconstituted CJC 1295 peptide should be kept at -20°C for long-term stability.